
David K. O. Dell
Examiner (ID: 15868, Phone: (571)272-9071 , Office: P/1625 )
| Most Active Art Unit | 1625 |
| Art Unit(s) | 1609, 1625, 1621 |
| Total Applications | 1704 |
| Issued Applications | 862 |
| Pending Applications | 109 |
| Abandoned Applications | 750 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19216202
[patent_doc_number] => 20240180906
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
[patent_app_type] => utility
[patent_app_number] => 18/283634
[patent_app_country] => US
[patent_app_date] => 2022-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19891
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283634
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/283634 | Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer | Mar 20, 2022 | Pending |
Array
(
[id] => 18748322
[patent_doc_number] => 11807618
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-07
[patent_title] => Thiophene derivatives as antiviral agents
[patent_app_type] => utility
[patent_app_number] => 17/697981
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35687
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 182
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697981
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/697981 | Thiophene derivatives as antiviral agents | Mar 17, 2022 | Issued |
Array
(
[id] => 18612235
[patent_doc_number] => 20230278967
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => NOVEL ANTI-OXIDANT COMPOUNDS AND COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/687654
[patent_app_country] => US
[patent_app_date] => 2022-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1908
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17687654
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/687654 | NOVEL ANTI-OXIDANT COMPOUNDS AND COMPOSITIONS | Mar 5, 2022 | Abandoned |
Array
(
[id] => 18878982
[patent_doc_number] => 20240002351
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => QUINAZOLIN-4-ONE AND THIENO[2,3-D]PYRIMIDIN-4-ONE INHIBITORS OF ERBB4 (HER4) FOR USE IN THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/276532
[patent_app_country] => US
[patent_app_date] => 2022-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30697
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 787
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18276532
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/276532 | QUINAZOLIN-4-ONE AND THIENO[2,3-D]PYRIMIDIN-4-ONE INHIBITORS OF ERBB4 (HER4) FOR USE IN THE TREATMENT OF CANCER | Mar 3, 2022 | Pending |
Array
(
[id] => 19216190
[patent_doc_number] => 20240180894
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/283373
[patent_app_country] => US
[patent_app_date] => 2022-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14858
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -71
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283373
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/283373 | METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR | Mar 2, 2022 | Pending |
Array
(
[id] => 17672631
[patent_doc_number] => 20220185798
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/685709
[patent_app_country] => US
[patent_app_date] => 2022-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22474
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17685709
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/685709 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | Mar 2, 2022 | Issued |
Array
(
[id] => 19034088
[patent_doc_number] => 20240083903
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => ARYL ETHER COMPOUNDS AS TEAD MODULATORS
[patent_app_type] => utility
[patent_app_number] => 18/264468
[patent_app_country] => US
[patent_app_date] => 2022-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18737
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 251
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264468
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/264468 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | Feb 14, 2022 | Pending |
Array
(
[id] => 18196431
[patent_doc_number] => 20230049950
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
[patent_app_type] => utility
[patent_app_number] => 17/672086
[patent_app_country] => US
[patent_app_date] => 2022-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36853
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17672086
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/672086 | Benzothia(di)azepine compounds and their use as bile acid modulators | Feb 14, 2022 | Issued |
Array
(
[id] => 19233663
[patent_doc_number] => 20240190855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => CDK INHIBITORS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/276946
[patent_app_country] => US
[patent_app_date] => 2022-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 98478
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 710
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18276946
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/276946 | CDK INHIBITORS AND METHODS OF USE THEREOF | Feb 10, 2022 | Pending |
Array
(
[id] => 19140535
[patent_doc_number] => 20240139327
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/276342
[patent_app_country] => US
[patent_app_date] => 2022-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13327
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18276342
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/276342 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Feb 8, 2022 | Pending |
Array
(
[id] => 19127164
[patent_doc_number] => 20240132517
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/276713
[patent_app_country] => US
[patent_app_date] => 2022-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14902
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18276713
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/276713 | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Feb 8, 2022 | Pending |
Array
(
[id] => 20349760
[patent_doc_number] => 20250346612
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-13
[patent_title] => INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES
[patent_app_type] => utility
[patent_app_number] => 18/264413
[patent_app_country] => US
[patent_app_date] => 2022-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47091
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264413
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/264413 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | Feb 6, 2022 | Pending |
Array
(
[id] => 18109490
[patent_doc_number] => 20230002370
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => DERIVATIVES OF RESIQUIMOD
[patent_app_type] => utility
[patent_app_number] => 17/665104
[patent_app_country] => US
[patent_app_date] => 2022-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17665104
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/665104 | Derivatives of resiquimod | Feb 3, 2022 | Issued |
Array
(
[id] => 18252951
[patent_doc_number] => 20230079990
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => LACTAMS AS CBL-B INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/592422
[patent_app_country] => US
[patent_app_date] => 2022-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 97397
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592422
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/592422 | LACTAMS AS CBL-B INHIBITORS | Feb 2, 2022 | Abandoned |
Array
(
[id] => 19127122
[patent_doc_number] => 20240132475
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => SUBSTITUTED PYRAZOLYL COMPOUNDS AS MALT-1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/264076
[patent_app_country] => US
[patent_app_date] => 2022-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18554
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264076
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/264076 | SUBSTITUTED PYRAZOLYL COMPOUNDS AS MALT-1 INHIBITORS | Feb 2, 2022 | Abandoned |
Array
(
[id] => 19112692
[patent_doc_number] => 20240124442
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/264216
[patent_app_country] => US
[patent_app_date] => 2022-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43497
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264216
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/264216 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | Feb 2, 2022 | Pending |
Array
(
[id] => 20143902
[patent_doc_number] => 12378229
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => GPR84 antagonists and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/649744
[patent_app_country] => US
[patent_app_date] => 2022-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 80693
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17649744
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/649744 | GPR84 antagonists and uses thereof | Feb 1, 2022 | Issued |
Array
(
[id] => 19127109
[patent_doc_number] => 20240132462
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE
[patent_app_type] => utility
[patent_app_number] => 18/274379
[patent_app_country] => US
[patent_app_date] => 2022-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6619
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 177
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18274379
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/274379 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | Jan 26, 2022 | Pending |
Array
(
[id] => 18779059
[patent_doc_number] => 11820751
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-21
[patent_title] => Urolithin derivatives and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/586294
[patent_app_country] => US
[patent_app_date] => 2022-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 70
[patent_figures_cnt] => 9
[patent_no_of_words] => 48875
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586294
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/586294 | Urolithin derivatives and methods of use thereof | Jan 26, 2022 | Issued |
Array
(
[id] => 19432403
[patent_doc_number] => 20240300901
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID
[patent_app_type] => utility
[patent_app_number] => 18/274354
[patent_app_country] => US
[patent_app_date] => 2022-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3852
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18274354
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/274354 | METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID | Jan 25, 2022 | Pending |